查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401900

到 2030 年治疗肌肉骨骼疾病药物的全球市场预测：按药物类型、疾病类型、治疗类型、给药途径、配销通路、最终用户和地区进行分析

Musculoskeletal Disorders Drugs Market Forecasts to 2030 - Global Analysis By Drug Type, By Disorder Type, Treatment Type, Route of Administration, Distribution Channel, End User, By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球肌肉骨骼疾病药物市场规模为 886 亿美元，预计在预测期内复合年增长率为 6.2%，到 2030 年将达到 1,351 亿美元。

肌肉骨骼疾病药物是一种旨在治疗影响肌肉、骨骼、关节、韧带和肌腱疾病的药物。这些疾病包括多种病症，例如关节炎、骨质疏鬆症和肌肉骨骼疼痛。这些疾病包括关节炎、骨质疏鬆症、肌肉骨骼疼痛等多种疾病，治疗药物旨在缓解症状、控制发炎和抑制疾病进展，有助于提高人们的运动能力和肌肉骨骼系统的整体健康。

据世界卫生组织称，全球有 17.1 亿人患有肌肉骨骼疾病，如类风湿性关节炎、骨关节炎、腰痛、颈部不适、骨折和其他伤害。

肌肉骨骼疾病盛行率上升

肌肉骨骼疾病盛行率的上升是肌肉骨骼疾病治疗市场的主要驱动因素。人口高龄化、久坐的生活方式和慢性疾病增加等因素导致关节炎、骨质疏鬆症和肌肉骨骼疼痛等肌肉骨骼问题的发生率增加。盛行率的增加使得对有效药物干预措施的需求激增。因此，製药公司正在投资研发，从而发现和生产创新药物并推动市场成长。

副作用和开发成本高

与某些药物相关的副作用的发生可能会阻碍患者的依从性和接受度。此外，广泛的研发和临床试验过程也会导致更高的开发成本。这些成本的财务负担阻碍了製药公司迅速将新的、潜在突破性的肌肉骨骼治疗推向市场，限制了患者的治疗选择，并限制了整体市场的增长和有效的治疗。药物的获取可能会受到影响。

肌萎缩侧索硬化症治疗药物的需求迅速增加

对肌萎缩性脊髓侧索硬化症药物的需求不断增长，为肌肉骨骼疾病药物市场带来了巨大的机会。随着意识的提高，越来越需要有效的治疗方法来解决这种使人衰弱的神经退化性疾病。投资开发肌萎缩侧索硬化症治疗方法的製药公司可以开拓这个新兴市场并满足患者未满足的医疗需求。此外，这也将有助于整体市场的成长。

医疗专业人员短缺

肌肉骨骼疾病通常需要风湿病专家、整形外科专家和物理治疗师等医疗专业人员的专门护理、诊断和治疗。专家的短缺导致患者照护延迟或不足，并妨碍对肌肉骨骼疾病的适当识别和管理。这种短缺可能会导致患者等待时间增加、获得专家意见的机会有限、实施综合治疗计划面临挑战等，从而影响整体市场成长。

COVID-19 的影响：

COVID-19大流行正在以各种方式影响肌肉骨骼疾病药物市场。封锁、卫生服务中断和经济不确定性正在影响患者获得治疗的机会。择期手术和常规预约的延误正在影响药物消耗模式。然而，人们对肌肉骨骼健康意识的提高和创新远端医疗解决方案的开发部分缓解了这段时期的这些挑战。

幼年特发性关节炎预计在预测期内将是最大的

由于幼年特发性关节炎病例数量不断增加，预计幼年特发性关节炎细分市场将在预测期内主导肌肉骨骼疾病治疗市场。对幼年特发性关节炎的认识不断提高、早期诊断和不断发展的治疗方案正在促进该领域的发展。药品的进步，加上对儿童医学的关注，正在推动研究和开发活动。此外，针对罕见疾病的监管支持和倡议正在进一步扩大该行业的市场份额。

预计医院业在预测期内复合年增长率最高。

医院领域的肌肉骨骼疾病药物市场可能会显着成长。医院是诊断、治疗和管理肌肉骨骼疾病的重要医疗中心。这些疾病的日益流行，加上人口高龄化的加剧，正在推动对专业医疗保健的需求。此外，随着医疗基础设施的不断扩大，医院领域有望显着成长。

占有率最大的地区

在预测期内，由于肌肉骨骼疾病的高盛行率、高龄化和完善的医疗基础设施，预计北美将主导肌肉骨骼疾病药物市场。此外，不断提高的意识、先进的诊断能力和积极的研究和开发也促进了市场的成长。此外，大型製药公司的存在和优惠的报销政策进一步巩固了北美的地位。

复合年增长率最高的地区：

在预测期内，由于人口高龄化加剧、生活方式改变以及肌肉骨骼疾病盛行率上升，预计亚太地区肌肉骨骼疾病药物市场将显着增长。此外，医疗基础设施的改善、意识的提高和可支配收入的增加也有助于增加获得先进药物的机会。此外，製药公司可能会扩大在该地区的业务，推动肌肉骨骼疾病治疗市场的显着成长。

免费客製化服务：

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球肌肉骨骼疾病治疗药物市场：依药物类型

  • 介绍
  • 止痛药
  • 皮质类固醇
  • 缓解疾病抗风湿药物 (DMARD)
  • 其他类型的药物

第六章全球肌肉骨骼疾病治疗市场：依疾病类型

  • 介绍
  • 纤维肌痛
  • 幼年特发性关节炎
  • 骨关节炎
  • 干癣性关节炎
  • 类风湿性关节炎
  • 脊椎关节炎
  • 其他类型的疾病

第七章全球肌肉骨骼疾病治疗市场：依治疗类型

  • 介绍
  • 药品
  • 外科手术
  • 治疗
  • 其他治疗类型

第八章肌肉骨骼疾病治疗药物的全球市场：依给药途径

  • 介绍
  • 口服
  • 胃肠外的
  • 其他给药途径

第九章全球肌肉骨骼疾病治疗药物市场：按配销通路

  • 介绍
  • 医院药房
  • 线上提供者
  • 零售药局和药局
  • 其他配销通路

第十章全球肌肉骨骼疾病治疗市场：依最终使用者分类

  • 介绍
  • 诊断中心
  • 医院
  • 风湿病学家
  • 专科诊所
  • 其他最终用户

第十一章全球肌肉骨骼疾病治疗药物市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司简介

  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • Amgen Inc.
  • AbbVie Inc.
  • Roche Holding AG
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Sanofi
  • GlaxoSmithKline plc
  • Regeneron Pharmaceuticals, Inc.
  • Biogen Inc.
  • AstraZeneca plc
  • Bristol Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
Product Code: SMRC24420

According to Stratistics MRC, the Global Musculoskeletal Disorders Drugs Market is accounted for $88.6 billion in 2023 and is expected to reach $135.1 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Musculoskeletal disorder drugs are pharmaceuticals designed to treat conditions affecting the muscles, bones, joints, ligaments, and tendons. These disorders encompass a range of conditions, such as arthritis, osteoporosis, and musculoskeletal pain. The drugs aim to alleviate symptoms, manage inflammation, and modify disease progression, contributing to improved mobility and overall musculoskeletal health for individuals affected by these disorders.

According to WHO, 1.71 billion individuals globally suffer from musculoskeletal diseases, such as rheumatoid arthritis, osteoarthritis, low back pain, neck discomfort, fractures, and other injuries.

Market Dynamics:

Driver:

Rising prevalence of musculoskeletal disorders

The escalating prevalence of musculoskeletal disorders acts as a key driver in the musculoskeletal disorders drugs market. Factors such as aging populations, sedentary lifestyles, and an increase in chronic conditions contribute to a growing incidence of musculoskeletal issues like arthritis, osteoporosis, and musculoskeletal pain. This rising prevalence necessitates a corresponding surge in demand for effective pharmaceutical interventions. Consequently, pharmaceutical companies are prompted to invest in research and development, leading to the discovery and production of innovative drugs, thereby propelling the growth of the market.

Restraint:

Adverse side effects and high development costs

The occurrence of adverse effects associated with certain drugs can hinder patient compliance and acceptance. Additionally, the extensive research, development, and clinical trial processes contribute to elevated development costs. The financial burden of these costs may impede pharmaceutical companies from bringing novel and potentially groundbreaking musculoskeletal drugs to market promptly, limiting treatment options for patients impacting the overall growth and accessibility of effective therapies in the market.

Opportunity:

Surging demand for amyotrophic lateral sclerosis drugs

The increasing demand for amyotrophic lateral sclerosis drugs presents a notable opportunity in the musculoskeletal disorders drugs market. As awareness grows, there is a rising need for effective treatments to address this debilitating neurodegenerative disease. Pharmaceutical companies investing in amyotrophic lateral sclerosis drug development can tap into this expanding market, meeting the unmet medical needs of patients. Additionally, this contributes to the overall growth of the market.

Threat:

Insufficient availability of healthcare professionals

Musculoskeletal disorders often require specialized care, diagnosis, and treatment from healthcare professionals such as rheumatologists, orthopedic specialists, and physical therapists. The shortage of these professionals can result in delayed or inadequate patient care, hindering the proper identification and management of musculoskeletal disorders. This scarcity may lead to increased patient wait times, limited access to expert opinions, and challenges in implementing comprehensive treatment plans, affecting overall market growth.

COVID-19 Impact:

The COVID-19 pandemic has impacted the musculoskeletal disorder drug market in various ways. Lockdowns, disruptions in healthcare services, and economic uncertainties have influenced patient access to treatments. Delayed elective procedures and routine care appointments have affected drug consumption patterns. However, increased awareness of musculoskeletal health and the development of innovative telehealth solutions have partially mitigated these challenges during this period.

The juvenile idiopathic arthritis segment is expected to be the largest during the forecast period

The juvenile idiopathic arthritis segment is poised to dominate the musculoskeletal disorders drugs market during the forecast period due to the increasing incidence of juvenile idiopathic arthritis cases. Rising awareness, early diagnosis, and evolving treatment options contribute to the segment's growth. Pharmaceutical advancements, coupled with a focus on pediatric healthcare, drive research and development activities. Additionally, favorable regulatory support and initiatives for rare diseases further propel the prominence of the segment in the market.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospital segment is primed for substantial growth in the musculoskeletal disorders drug market. Hospitals serve as key healthcare centers for musculoskeletal disorder diagnosis, treatment, and management. The increasing prevalence of these disorders, coupled with a rising aging population, drives the demand for specialized medical care. Additionally, combined with the expanding healthcare infrastructure, the hospital segment is poised for significant growth.

Region with largest share:

Over the forecast period, North America is expected to dominate the Musculoskeletal Disorders Drugs market due to the high prevalence of musculoskeletal disorders, an aging population, and a well-established healthcare infrastructure. Additionally, increasing awareness, advanced diagnostic capabilities, and robust research and development activities contribute to the market's growth. Moreover, the presence of major pharmaceutical companies and favorable reimbursement policies further solidify North America's position.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is poised for substantial growth in the Musculoskeletal Disorders Drugs market due to increasing aging populations, lifestyle changes, and a rising prevalence of musculoskeletal disorders. Additionally, improving healthcare infrastructure, growing awareness, and rising disposable incomes contribute to increased accessibility to advanced medications. Moreover, pharmaceutical companies are likely to expand their presence in the region, fostering significant growth in the musculoskeletal disorders drugs market.

Key players in the market:

Some of the key players in Musculoskeletal Disorders Drugs Market include Pfizer Inc., Novartis AG, Johnson & Johnson, Amgen Inc., AbbVie Inc., Roche Holding AG, Merck & Co., Inc., Eli Lilly and Company, Sanofi, GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., Biogen Inc., AstraZeneca plc, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd. and Gilead Sciences, Inc.

Key Developments:

In Jun 2022, Pfizer came into collaboration with Sirana Pharma, a Germany-based developer of a biotechnology company. The collaboration involves investigating treatment for a rare bone disease, through leveraging Sirana's microRNA targeting approach.

In March 2022, Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, the company aimed to adjoin the amazing pipeline and experience of Arena Pharmaceuticals to Pfizer's Immunology and swelling healing area, assisting further motive of advancement boost to change the lives of patients with the immuno-inflammatory illness.

Drug Types Covered:

  • Analgesics
  • Corticosteroids
  • Disease-Modifying Antirheumatic Drugs (DMARDs)
  • Other Drug Types

Disorder Types Covered:

  • Fibromyalgia
  • Juvenile Idiopathic Arthritis
  • Osteoarthritis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Spondylarthritis
  • Other Disorder Types

Treatment Types Covered:

  • Medication
  • Surgery
  • Therapy
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Other Route of Administrations

Distribution Channels Covered:

  • Hospital Pharmacy
  • Online Providers
  • Retail Pharmacy and Drug Stores
  • Other Distribution Channels

End Users Covered:

  • Diagnostic Centers
  • Hospitals
  • Rheumatologists
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Musculoskeletal Disorders Drugs Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Analgesics
  • 5.3 Corticosteroids
  • 5.4 Disease-Modifying Antirheumatic Drugs (DMARDs)
  • 5.5 Other Drug Types

6 Global Musculoskeletal Disorders Drugs Market, By Disorder Type

  • 6.1 Introduction
  • 6.2 Fibromyalgia
  • 6.3 Juvenile Idiopathic Arthritis
  • 6.4 Osteoarthritis
  • 6.5 Psoriatic Arthritis
  • 6.6 Rheumatoid Arthritis
  • 6.7 Spondylarthritis
  • 6.8 Other Disorder Types

7 Global Musculoskeletal Disorders Drugs Market, By Treatment Type

  • 7.1 Introduction
  • 7.2 Medication
  • 7.3 Surgery
  • 7.4 Therapy
  • 7.5 Other Treatment Types

8 Global Musculoskeletal Disorders Drugs Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Parenteral
  • 8.4 Other Route of Administrations

9 Global Musculoskeletal Disorders Drugs Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacy
  • 9.3 Online Providers
  • 9.4 Retail Pharmacy and Drug Stores
  • 9.5 Other Distribution Channels

10 Global Musculoskeletal Disorders Drugs Market, By End User

  • 10.1 Introduction
  • 10.2 Diagnostic Centers
  • 10.3 Hospitals
  • 10.4 Rheumatologists
  • 10.5 Specialty Clinics
  • 10.6 Other End Users

11 Global Musculoskeletal Disorders Drugs Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Pfizer Inc.
  • 13.2 Novartis AG
  • 13.3 Johnson & Johnson
  • 13.4 Amgen Inc.
  • 13.5 AbbVie Inc.
  • 13.6 Roche Holding AG
  • 13.7 Merck & Co., Inc.
  • 13.8 Eli Lilly and Company
  • 13.9 Sanofi
  • 13.10 GlaxoSmithKline plc
  • 13.11 Regeneron Pharmaceuticals, Inc.
  • 13.12 Biogen Inc.
  • 13.13 AstraZeneca plc
  • 13.14 Bristol Myers Squibb Company
  • 13.15 Takeda Pharmaceutical Company Limited
  • 13.16 F. Hoffmann-La Roche Ltd.
  • 13.17 Gilead Sciences, Inc.

List of Tables

  • Table 1 Global Musculoskeletal Disorders Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Musculoskeletal Disorders Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 3 Global Musculoskeletal Disorders Drugs Market Outlook, By Analgesics (2021-2030) ($MN)
  • Table 4 Global Musculoskeletal Disorders Drugs Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 5 Global Musculoskeletal Disorders Drugs Market Outlook, By Disease-Modifying Antirheumatic Drugs (DMARDs) (2021-2030) ($MN)
  • Table 6 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 7 Global Musculoskeletal Disorders Drugs Market Outlook, By Disorder Type (2021-2030) ($MN)
  • Table 8 Global Musculoskeletal Disorders Drugs Market Outlook, By Fibromyalgia (2021-2030) ($MN)
  • Table 9 Global Musculoskeletal Disorders Drugs Market Outlook, By Juvenile Idiopathic Arthritis (2021-2030) ($MN)
  • Table 10 Global Musculoskeletal Disorders Drugs Market Outlook, By Osteoarthritis (2021-2030) ($MN)
  • Table 11 Global Musculoskeletal Disorders Drugs Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
  • Table 12 Global Musculoskeletal Disorders Drugs Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 13 Global Musculoskeletal Disorders Drugs Market Outlook, By Spondylarthritis (2021-2030) ($MN)
  • Table 14 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Disorder Types (2021-2030) ($MN)
  • Table 15 Global Musculoskeletal Disorders Drugs Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 16 Global Musculoskeletal Disorders Drugs Market Outlook, By Medication (2021-2030) ($MN)
  • Table 17 Global Musculoskeletal Disorders Drugs Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 18 Global Musculoskeletal Disorders Drugs Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 19 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 20 Global Musculoskeletal Disorders Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 21 Global Musculoskeletal Disorders Drugs Market Outlook, By Oral (2021-2030) ($MN)
  • Table 22 Global Musculoskeletal Disorders Drugs Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 23 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 24 Global Musculoskeletal Disorders Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 25 Global Musculoskeletal Disorders Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 26 Global Musculoskeletal Disorders Drugs Market Outlook, By Online Providers (2021-2030) ($MN)
  • Table 27 Global Musculoskeletal Disorders Drugs Market Outlook, By Retail Pharmacy and Drug Stores (2021-2030) ($MN)
  • Table 28 Global Musculoskeletal Disorders Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 29 Global Musculoskeletal Disorders Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 30 Global Musculoskeletal Disorders Drugs Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 31 Global Musculoskeletal Disorders Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 32 Global Musculoskeletal Disorders Drugs Market Outlook, By Rheumatologists (2021-2030) ($MN)
  • Table 33 Global Musculoskeletal Disorders Drugs Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 34 Global Musculoskeletal Disorders Drugs Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.